ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer

Michelle Wilson ,Domenica Lorusso,Rebecca Kristeleit ,Sandra Goble,Ramez N. Eskander ,Kevin K. Lin ,Shannon N. Westin ,Danny Shih,Bradley J. Monk ,Stephanie Hume,Amit M. Oza ,Keiichi Fujiwara,David M. O’malley ,Iain A. Mcneish ,Tamar Safra,Robert L. Coleman ,Thomas J. Herzog ,Frederik Marmé,Ana Oaknin,Lara Maloney,Nikolay Grechko

doi:10.1136/ijgc-2021-002933

ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer

Michelle Wilson , Domenica Lorusso

Open Access

https://doi.org/10.1136/ijgc-2021-002933

Copy DOI

#Rucaparib In Combination #Ovarian Cancer + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

BackgroundThe optimal treatment strategy for women with newly diagnosed ovarian cancer has yet to be determined. Poly(ADP-ribose) polymerase (PARP) inhibitors have demonstrated substantial improvement in progression-free survival as monotherapy maintenance...

Full Text